Naseema Gangat, MBBS discusses the clinical utility of momelotinib and JAK inhibitor selection in treatment-naive myelofibrosis.
Naseema Gangat, MD
Advertisement
Articles by Naseema Gangat, MD
Naseema Gangat, MBBS, on evolution of JAK inhibitors for the treatment of patients with myelofibrosis.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Sacituzumab Govitecan Approved in Europe for First-Line PD-L1 Inhibitor–Ineligible TNBC
2
Allogeneic BCMA CAR T-Cell Therapy CT0596 Elicits 100% ORR in R/R Myeloma and Plasma Cell Leukemia
3
NCCN Includes PCR ctDNA-MRD Testing in MIBC Treatment Algorithm
4
Tirabrutinib May Shift the R/R PCNSL Treatment Paradigm Toward Improved Tolerability
5